Remibrutinib (Rhapsido) for Chronic Hives: A New Oral Alternative to Injections

If you live with chronic hives, you know the exhausting reality: antihistamines that barely touch the symptoms, unpredictable flares that disrupt sleep and work, and, for those who have progressed to injectable biologics, the ongoing burden of clinic appointments and injections every few weeks.

For many patients, omalizumab (Xolair) has been the most effective option, but it requires subcutaneous injections every four weeks, which creates real adherence challenges and practical friction.

That picture is shifting. On September 30, 2025, the U.S. Food and Drug Administration approved Rhapsido, the brand name for remibrutinib, as the first targeted oral therapy for chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment.

This makes remibrutinib chronic hives treatment a real clinical option, not just a research concept, and positions it as the first oral treatment for chronic urticaria to work through a targeted immune mechanism rather than simply blocking histamine after it has already been released.

This article explains how remibrutinib works, what the clinical evidence shows, how it compares to existing injection-based treatments, who the best candidates are, and what patients need to know before discussing it with their doctor.

Read More: Hives or Rash? How to Tell the Difference and When to See a Doctor

What Is Remibrutinib (Rhapsido) and How Does It Work?

Remibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, a class of drugs that blocks a specific enzyme involved in immune cell signaling. BTK sits near the start of the inflammatory cascade in mast cells and basophils, the immune cells that drive the characteristic wheals and itch of chronic spontaneous urticaria. By blocking BTK, remibrutinib interrupts that cascade upstream, before histamine and other inflammatory mediators are released.

This is a fundamentally different strategy than antihistamines, which work downstream by blocking histamine receptors after the mediators have already been released into tissue. It also differs from omalizumab, which targets IgE antibodies to reduce one specific pathway of mast cell activation.

How Remibrutinib Targets Mast Cell Activation

In people with chronic spontaneous urticaria (CSU), mast cells and basophils are abnormally activated through immune pathways involving IgE receptors and IgG antibodies. When the IgE receptor on these cells is engaged, it triggers BTK signaling, which ultimately leads to degranulation: the rapid release of histamine, cytokines, and other proinflammatory mediators that produce the red, raised, itchy wheals and tissue swelling.

Remibrutinib covalently binds to BTK and blocks this signaling regardless of which immune pathway initially triggered activation. A peer-reviewed narrative published in Annals of Medicine and Surgery following the FDA approval described remibrutinib as providing “upstream control of disease activity” by interrupting the inflammatory cascade “at its source,” rather than managing symptoms after the inflammatory response is already underway.

Why This Mechanism Is Different From Antihistamines and Biologics

Antihistamines compete with histamine at receptor sites, offering partial symptom relief when taken before or shortly after exposure. They do not prevent mast cell degranulation. Omalizumab binds free IgE in the blood, reducing one specific trigger of mast cell activation, but it does not directly block the BTK signaling pathway and requires monthly injections.

Remibrutinib addresses a shared pathway that is active regardless of whether CSU is driven by IgE-mediated or autoimmune mechanisms, giving it theoretical activity across a broader range of disease subtypes.

Who Might Benefit From Remibrutinib for Chronic Hives?

Remibrutinib is specifically approved for adults with CSU who remain symptomatic despite H1-antihistamine treatment. Current guidelines recommend second-generation antihistamines as first-line therapy and allow dose increases up to four times the standard dose before escalating.

Despite this, the REMIX-1 and REMIX-2 clinical trials noted that more than 50 percent of patients continue to have symptoms on antihistamines, and up to 75 percent remain symptomatic even at four-fold the standard dose. These patients are exactly the population for whom remibrutinib is intended.

Dr. Robert A. Snyder, MD, FAAD, a dermatologist at Riverchase Dermatology and Cosmetic Surgery in Florida and a REMIX trial investigator, told Managed Healthcare Executive that he envisions clinicians prescribing remibrutinib after CSU patients do not respond to second-generation antihistamines at their maximized doses, noting it might be prescribed before, or instead of, omalizumab.

Some patients find monthly injection schedules impractical, particularly those without reliable transportation, needle phobia, or demanding work schedules that make clinic appointments difficult. Others may have had partial or inconsistent responses to omalizumab. For these patients, an effective oral alternative that can be taken at home without laboratory monitoring is a meaningful clinical advantage.

Rhapsido received full FDA approval on September 30, 2025, based on the phase 3 REMIX-1 and REMIX-2 trials. It is currently approved in the United States for adults with CSU inadequately controlled by H1-antihistamines.

Novartis has submitted applications to global health authorities, and approval in additional regions was anticipated through 2025 and 2026. As of the article date, it is also under investigation for chronic inducible urticaria, hidradenitis suppurativa, and food allergy.

Remibrutinib vs. Injection Treatments: What Is Different?

The most immediately practical difference is delivery method. Remibrutinib is taken as a 25 mg oral tablet twice daily, at home, without clinic visits for administration. Omalizumab requires a subcutaneous injection every four weeks, typically administered in a clinical setting with an observation period for anaphylaxis risk.

For patients managing chronic disease over the years, this logistical difference has real implications for adherence and quality of life. Omalizumab works by binding free IgE antibodies in circulation, reducing the pool of IgE available to sensitize mast cells.

This is effective when IgE-mediated pathways drive disease activity, but it may be less effective in patients whose CSU is driven primarily by autoimmune mechanisms involving IgG antibodies targeting the IgE receptor itself. Remibrutinib blocks BTK downstream of both pathways, giving it activity across both IgE-mediated and autoimmune subtypes of CSU.

Dr. Giselle Mosnaim, MD, MS, an allergist and immunologist at Endeavor Health and clinical associate professor at the University of Chicago Pritzker School of Medicine, stated in the Novartis FDA approval announcement that remibrutinib “expands beyond existing injectable treatments and gives patients an oral option that can easily be incorporated into their daily lives.”

Direct head-to-head comparisons between remibrutinib and omalizumab have not yet been conducted in a randomized controlled trial, which has been noted as a limitation of the current evidence base. 

A letter published in the New England Journal of Medicine in May 2025 pointed out that the REMIX development program missed the opportunity to compare remibrutinib directly with omalizumab, which would have made the data substantially more informative for clinical decision-making. Both drugs appear effective in their respective trial populations, but comparisons across different trials are inherently imprecise.

Read More: Foods That May Trigger Hives and What to Eat Instead

What Does the Research Say So Far?

The pivotal evidence for remibrutinib comes from the REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials, two identical multicenter, double-blind, randomized, placebo-controlled studies enrolling a combined 925 patients with CSU whose symptoms persisted despite second-generation antihistamines. Patients received oral remibrutinib 25 mg twice daily or placebo in a 2:1 ratio.

Published in the New England Journal of Medicine in March 2025, the results showed that remibrutinib produced a significantly greater reduction in the weekly Urticaria Activity Score (UAS7) at week 12 compared to placebo: a least-squares mean change of -20.0 vs. -13.8 in REMIX-1 and -19.4 vs. -11.7 in REMIX-2, both with P less than 0.001.

Approximately 31 percent of patients in REMIX-1 and 28 percent in REMIX-2 achieved a UAS7 of zero, meaning complete symptom resolution, by week 12.

Prof. Martin Metz, MD, Professor of Dermatology at Charité Universitätsmedizin Berlin and co-lead investigator of the REMIX studies, noted in a Novartis announcement that remibrutinib “blocks the BTK cascade and inhibits the release of histamine” and described it as “an important investigational treatment for CSU.”

How Quickly Symptoms Improved in Studies

One of the most clinically striking findings was the speed of response. Symptom improvement, as measured by urticaria activity scores, was detectable as early as week one. 

A 2025 systematic review and meta-analysis published in the Journal of Allergy and Clinical Immunology: In Practice, pooling data from three randomized controlled trials and two single-arm studies, found that significantly better disease control was achieved as early as week two, with a risk ratio of 6.81 for controlled disease versus placebo.

This rapid onset is clinically meaningful for patients who have been living with uncontrolled symptoms for months or years.

Long-Term Data and What Remains Unknown

Fifty-two-week results from the REMIX studies, published in the Journal of Allergy and Clinical Immunology in October 2025, confirmed sustained efficacy over one year. The mean UAS7 change from baseline at week 52 was approximately -23, and approximately 60 to 65 percent of patients had no sleep or activity problems from CSU at that point. Adverse event rates remained comparable to placebo throughout.

Open questions include the optimal duration of treatment, what happens to symptoms after stopping remibrutinib, and how it performs across broader real-world populations, including those with significant comorbidities. An ongoing extension study is examining these questions.

Long-term cardiovascular and hematologic effects of BTK inhibition, which have been concerns with this drug class in oncology applications at much higher doses, are being monitored, though the doses and mechanisms in CSU differ substantially from oncology settings.

Potential Benefits of Remibrutinib

For a condition that can persist for years or decades, the ability to take a twice-daily tablet at home removes a substantial logistical burden. No injection site reactions, no monthly clinic appointments for administration, and no requirement for routine laboratory monitoring, a point specifically noted in the FDA approval documentation, together make remibrutinib practically accessible in a way that injectable biologics are not.

The clinical evidence suggests symptom relief beginning within the first week of treatment, with statistically significant improvements over placebo by week two. For patients whose daily life is significantly disrupted by chronic hives, early response is an important therapeutic quality.

Beyond the obvious convenience, reducing clinic visit frequency has real value for patients in rural areas with limited access to specialists, for those with employment constraints, and for those who find the ongoing schedule of injection appointments difficult to maintain. The absence of required laboratory monitoring further simplifies long-term management.

Possible Side Effects and Safety Considerations

The most frequently reported adverse events with remibrutinib in the REMIX trials were nasopharyngitis, headache, nausea, and abdominal pain. Upper respiratory tract infections occurred at a modestly higher rate than in the placebo group.

A notably higher rate of petechiae, small superficial skin hemorrhages, was observed in the remibrutinib group compared to placebo (3.8 percent vs. 0.3 percent), though these were generally mild and did not result in treatment discontinuation in most cases.

BTK inhibitors used in oncology at higher doses have been associated with serious cardiovascular effects, including atrial fibrillation, bleeding, and infection risk. Remibrutinib was specifically designed for high selectivity at lower doses to minimize off-target effects, and these serious events were not observed at the rates seen in oncology settings in the CSU trials.

However, the long-term safety data in the CSU at scale is still accumulating.

Despite the convenience of oral dosing, remibrutinib is a targeted immunomodulatory therapy. Treatment decisions should involve a dermatologist or allergist familiar with CSU management, particularly because the optimal placement of remibrutinib relative to omalizumab in treatment sequencing is still being defined.

Patients on anticoagulants or with bleeding disorders should discuss risks carefully before starting. Women of childbearing age should discuss contraceptive needs, as BTK inhibitor effects during pregnancy are not fully characterized.

How Is Remibrutinib Taken?

Remibrutinib is taken as 25 mg orally twice daily with or without food. Consistency matters: the drug’s efficacy depends on maintaining adequate drug concentrations, and missed doses reduce the therapeutic effect. Patients should not double a dose to make up for a missed one.

Because the drug does not require laboratory monitoring on a scheduled basis, adherence tracking depends more on patient self-management and regular clinical follow-up than on test results.

Treatment duration is individualized. The REMIX studies followed patients for up to 52 weeks, and the ongoing extension trial is examining whether patients can safely taper or discontinue treatment after achieving sustained remission.

Is Remibrutinib Available Yet? Access and Approval Status

Rhapsido (remibrutinib) received FDA approval in the United States on September 30, 2025, and was commercially available shortly thereafter. Novartis had initiated submissions to health authorities in Europe and other regions in the second half of 2024, with approval timelines varying by jurisdiction.

Insurance coverage and cost are active considerations. As a newly approved branded therapy, remibrutinib falls into the specialty drug tier in most formularies, and prior authorization requirements are common.

Patients should expect to work through prior authorization documentation with their prescriber, particularly demonstrating prior treatment with antihistamines and the documented inadequacy of that treatment. Patient assistance programs through Novartis may be available for eligible patients.

When to Consider Switching From Injections to an Oral Option

Switching from an effective regimen carries risk, and patients whose condition is well-controlled on omalizumab should have a careful conversation with their provider before making changes.

Switching may be worth discussing when injection adherence is genuinely problematic, when omalizumab produces only partial control, when patients prefer an oral regimen for quality-of-life reasons, or when access to injectable therapy is limited.

Signs that current treatment may not be working well enough include persistent daily symptoms despite adherence to the injection schedule, ongoing sleep disruption, significant quality-of-life impairment, or frequent breakthrough flares requiring additional treatment.

Questions to bring to your physician include: Is my disease pattern consistent with the population that responded in the REMIX trials? What should I expect during the transition period? Are there any interactions with my current medications? What is the plan if remibrutinib does not control my symptoms adequately?

Practical Tips for Managing Chronic Hives Alongside Medication

Even with effective targeted treatment, lifestyle factors influence symptom burden. Identifying and minimizing known triggers, which commonly include stress, heat, alcohol, NSAIDs, and certain food additives, reduces the inflammatory load on an already hyperactive immune system.

Keeping a hives diary, tracking symptom timing, severity, and potential triggers, helps both patients and clinicians evaluate treatment response and identify modifiable contributors. Skin barrier support through gentle, fragrance-free skincare reduces irritation from secondary scratching.

Staying well hydrated and managing sleep quality supports overall immune regulation. Regular follow-up with a dermatologist or allergist every three to six months while on remibrutinib allows for treatment response assessment and monitoring for emerging side effects.

Read More: How to Get Rid of Hives

Key Takeaway

Remibrutinib chronic hives treatment represents a genuine advance in the oral treatment for chronic urticaria, addressing a mechanism upstream of histamine release in a way that antihistamines cannot and delivering results in tablet form that previously required injections.

The REMIX clinical trials evidence shows rapid, sustained, and clinically significant symptom reduction in patients with antihistamine-resistant CSU, with a safety profile comparable to placebo in the trial timeframe.

Whether it becomes a first-choice alternative to Xolair injections or a second-line option depends on how future comparative data and real-world evidence shape treatment guidelines. As an alternative to Xolair injections, remibrutinib offers genuine advantages in convenience, delivery method, and mechanism breadth.

As a BTK inhibitor for hives treatment, it brings a new biological target into routine dermatologic and allergologic practice. But it is not appropriate for everyone, and the final decision about treatment sequence, switching, or combination belongs to the patient and their specialist together, informed by individual disease characteristics, comorbidities, and practical circumstances.